NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
business operation functions and reports to TPNA President Alan MacKenzie. “We are delighted to have Mark join our executive team,” Mr. MacKenzie says. “He will play an important role in TPNA’s contin ued growth and his extensive background and general management experience in the phar maceutical industry will be beneficial as we manage the increasing complexity of our busi ness.” Most recently, Mr. Booth was at the biotech company Immunex, where he served as general manager and senior VP of commer cial operations. In his new position, Mr. Daly takes on cer tain global marketing responsibilities for the type 2 diabetes drug Actos. He also is respon sible for the creation of a business develop ment function at TPNA. Mr. Daly most recently served as VP of marketing for TPNA, Lincolnshire, Ill., and has been with the company since its inception in 1998. He is a graduate of the University of Notre Dame and earned an M.B.A. from Northwestern University.
Akihiko MATSUBARA Yamanouchi Pharmaceutical names president of U.S. division
Akihiko Matsubara has been promoted to president and director of Yamanouchi America Inc., the U.S. division of Japanese pharmaceutical concern Yamanouchi Pharmaceutical Co. Ltd. Mr. Matsubara, who has been at Yamanouchi for more than 20 years, replaces Nicholas L. Teti, who has resigned. In March 2001, Mr. Matsubara was named senior VP of Yamanouchi America to assist in the formation of the business and sales opera tions. “Akihiko has been instrumental in the cre ation and corporate planning strategies of our U.S. growthexpansion process,” says Dr. Toichi Takenaka, Yamanouchi Pharmaceutical president and CEO. “He brings the highest level of business development expertise and leadership experience to our team. Under his direction, Yamanouchi America will be well positioned to enter the U.S. pharmaceutical market with new and innovative products.” Mr. Matsubara has a B.A. in Economics from Hitotaubashi University, in Japan. Werner WENNING Bayer’s CFO to take the helm Announcing a changing of the guard, Bayer AG has announced its chief financial officer, Werner Wenning, will take over from longtime CEO Manfred Schneider in April 2002. “I firmly believe that Werner Wenning is the right man for the job,” says Hermann Josef Strenger, supervisory board chairman. “His decisiveness and perseverance are convincing arguments in his favor.” At a shareholders meeting on April 26, 2002, Dr. Schneider, 62, will stand for elec tion as chairman of the supervisory board. Mr. Wenning has been at the German pharmaceutical concern in various capacities since 1966. The executive also holds a number of offices outside Bayer, including as a mem ber of several supervisory boards. Biotech POOL Dr. Burt ADELMAN Dr. Sylvie GREGOIRE Biogen fills two executive positions Burt Adelman, M.D., has been appointed executive VP of research and development at Biogen Inc. Dr. Adelman previously was Bio gen’s VP of medical research, having joined the company in 1991. Additionally, Dr. Adel man has held an appointment as a lecturer of medicine at Harvard Medical School since 1992. Dr. Adelman received his B.S. from Trinity College and earned his M.D. from Cor nell Medical College. Also at the company, Sylvie Gregoire, Pharm. D., has been named as executive VP of technical operations, with responsibility for manufacturing, manufacturing sciences, engi neering, product development, and quality. Dr. Gregoire most recently was Cambridge, Mass.based Biogen’s VP of manufacturing and has more than 15 years of international and U.S. experience in the pharmaceutical industry. Her career has included positions in manufac TALENT POOL Brenda J. BLANCHARD Former Wisconsin Secretary of Commerce to head Novartis’ alliance development Novartis Pharmaceuti cals Corp. has appointed Brenda J. Blanchard as VP of alliance develop ment. “Brenda brings a wealth of business devel opment experience in areas of growing impor tance to our company,” says Paulo Costa, CEO of the East Hanover, N.J.based company. “By expanding and improving our interface with large employers, insurance companies, advoca cy groups, and state government policy mak ers, our products and services can be better understood and represented.” Ms. Blanchard was formerly Wisconsin’s Secretary of Commerce. She will relocate to Washington, D.C., where she will work close ly with the Novartis governmentrelations team. Mark BOOTH Richard DALY Takeda announces marketing appointments In a shakeup of its senior ranks, Takeda Pharmaceuticals North America Inc. has appointed Mark Booth to the newly created position of executive VP, and promoted Richard Daly to senior VP of marketing. Mr. Booth oversees all sales, marketing and Pharma POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY TALENT pool 77 PharmaVOICE N o v e mb e r / D e c e m b e r 20 01 turing, regulatory affairs, program manage ment, clinical research, and clinical pharmacol ogy for new drug development. Jeffrey H. BUCHALTER Ilex Oncology names president Jeffrey H. Buchalter, 44, has been appoint ed president of Ilex Oncology Inc., positioning the company to become a leading oncology pharmaceutical entity. Mr. Buchalter has more than 20 years of pharmaceutical experience and has held key positions at a number of multinational pharmaceutical companies. He assumes the role of president from Ilex co founder Richard L. Love, 58, who continues as CEO. In his new role reporting to Mr. Love, Mr. Buchalter is responsible for advancing Ilex Oncology to a fully integrated pharmaceutical company. He assumes responsibility for all ongoing operations of the company and also continues to serve on the Ilex board, which he joined in February. Throughout his career, Mr. Buchalter has spearheaded the development and commer cialization of a number of cuttingedge prod ucts to meet the needs of healthcare profes sionals and patients worldwide. From 1997 to 2000, as group VP and head of the worldwide oncology franchise at Pharmacia Corp., he was pivotal in building the global oncology fran chise through new product approvals and launches, and in the strategic acquisition of Sugen’s technologybased drug discovery and development platform. From 1993 to 1997, as group director for the women’s healthcare business of American Home Products, WyethAyerst Laboratories, he played a key role in the lifecycle manage ment of its multibilliondollar drug Premarin and helped to develop and commercialize the hormone replacement therapy Prempro. While with Schering Plough Corp. in the late 1980s and early 1990s, he led the launch of interferon (Alpha A), one of the first cytokines to be approved for hairy cell leukemia. Mr. Buchalter holds a B.S. degree in finance from Seton Hall University and an M.B.A. in marketing from Temple University. Tien T. BUI Karen E. HARTWIG ViroLogic names sales and marketing executives ViroLogic Inc. has promoted Tien T. Bui to VP of sales and Karen E. Hartwig to VP of marketing. The executives replace Robin Toft, VP, of sales and marketing, who has left the company. “Karen and Tien have been integrally involved and are largely responsible for the successful launch and commercialization of our lead products and already have a proven track record in executing our marketing and sales plans,” says Bill Young, ViroLogic’s chairman and CEO. Ms. Bui is charged with managing all physician, healthcare provider, and laboratory sales operations related to ViroLogic’s assays. As director of field sales at ViroLogic, she has recruited and trained most of the company’s 18person salesforce, and led them to consis tently meet or exceed sales goals. Before join ing ViroLogic, Ms. Bui served as DuPont Phar maceuticals’ western business unit virology field director, responsible for $60 million in product sales. Ms. Bui received her bachelor of science degree in international business from San Francisco State University and also studied abroad at The University of Liege, Belgium. Before joining ViroLogic, Ms. Hartwig was senior director of marketing for ProDuct Health Inc., a company that develops diagnos tic devices for breast cancer. Ms. Hartwig has a master’s degree in business administration from the Walter A. Haas School of Business at the University of California, Berkeley, and a bachelor’s degree in government from Dart mouth College. Scott BURTON Barry LABINGER Laura HAMILL Immunex expands commercial operation with new sales team To take advantage of the growing demand for Enbrel and potential new uses for the prod uct, Immunex Corp. is building an Enbrel salesforce. Enbrel is approved to treat rheuma toid arthritis and is undergoing clinical trials for the treatment of psoriasis, a skin disease. The U.S. salesforce will work with Wyeth Ayerst, a division of American Home Products Corp., which has been selling Enbrel since its launch in 1998. Scott Burton is leading the team as VP of sales for Enbrel, with responsibility for hiring and managing the new sales team. Mr. Burton has more than 14 years of experience in field sales and product management, including work in the managed care, cardiovascular and antiinfective markets. Most recently, he was business director of regional operations at BristolMyers Squibb Co. He has a B.S. in marketing from Utah State University. In a separate move, Immunex has promot ed Laura Hamill to VP of marketing for Enbrel. Before joining Immunex last year, Ms. Hamill was executive VP at Klemtner Adver tising in New York where she oversaw adver tising and marketing programs for a number of brands, including Enbrel. She holds a bach elor’s degree in marketing from the Universi ty of Arizona. In a move to expand its commercial opera tions, Immunex has announced a new general manager to oversee the sales, marketing, and development of franchises for both Enbrel and specialty therapeutics. Barry Labinger, VP of marketing for Enbrel, has been promoted to senior VP and general manager at the company. Since joining Immunex in June 2000, Mr. Labinger has led initiatives to build the franchise for Enbrel through programs that have established the product’s leadership position. Mr. Labinger has more than 14 years of healthcare industry experience, primarily in marketing and sales. Before joining Immunex, he oversaw the marketing for the U.S. diabetes franchise at BristolMyers Squibb Co. He has a bachelor’s degree with a major in economics from Northwestern University and has a mas ters of management degree from the Kellogg School of Management at Northwestern Uni versity. Michael FURLONG Phylos names senior director of business development In a move to strength en Phylos Inc.’s develop ment team, the biotech company has named Michael Furlong as senior director of business devel opment, with responsibil ities for licensing and strategic collaborations. Mr. Furlong has more than 10 years of experience in the biopharmaceutical industry, and joins Phylos, Lexington, Mass., from Mosaic Technologies, where he held the posi tion of VP of business development. Mr. Fur long received his M.B.A. from the W. Paul Stillman School of Business at Seton Hall Uni versity in 1997, and his B.S. from the U.S. Military Academy at West Point in 1985. Lance K. GORDON,Ph.D. VaxGen names vaccine expert as CEO Lance K. Gordon, Ph.D., who has more than 20 years of experience in the vaccine industry, has been appointed CEO of VaxGen Inc. Widely rec ognized in the vaccine industry, Dr. Gordon served as CEO of two vac TALENT pool cine companies and invented a vaccine for childhood meningitis before joining VaxGen. “Having examined the strong scientific rationale for AIDSVAX, the company’s vac cine, I am convinced that VaxGen has extraor dinary potential both as a business and as a major force in the struggle against AIDS,” Dr. Gordon says. Dr. Gordon last served as director of North American operations of Peptide Therapeutics Group, now Acambis Plc., a developer of vac cines for infectious diseases. From 1990 to 1999, Dr. Gordon was pres ident and CEO of OraVax Inc., where he secured a 20year contract to develop, manu facture, store, and manage a 40million dose stockpile of smallpox vaccine for the Centers for Disease Control and Prevention. He also created partnerships and similar relationships with Aventis Pasteur, Medeva, IDEC, BioRe liance, and McKesson HBOC. Dr. Gordon received a Ph.D. in biomedical science, immunology, from the University of Connecticut and completed his postdoctoral fellowship at the Howard Hughes Medical Research Institute. Michael J. HOWERTON ImClone names VP of business development Michael J. Howerton has joined ImClone Systems Inc. as VP, business development. In this newly created position, Mr. Howerton is responsible for the pursuit and development of new business opportunities, including acquisi tions, product inlicensing and outlicensing, and strategic alliances. Before joining ImClone Systems, Mr. How erton built a 25year career at BristolMyers Squibb Co. In his most recent position at BMS, Mr. Howerton served as VP, financial analysis and assistant controller, from 1998 to 2001. Mr. Howerton earned a bachelor of arts in English from Holy Cross College and a mas ter’s degree in business administration from Iona College. C.Thomas JOHNS Gary SISKOWSKI Nabi names new heads of manufacturing operations,sales and marketing Nabi has announced two senior manage ment positions within the company. C. Thomas Johns, previously VP of laboratory services and diagnostic products, has been named senior VP of manufacturing opera tions. Gary Siskowski, formerly VP of business development, has been named senior VP of sales and marketing. Mr. Johns is charged with overseeing the management of Nabi’s new Boca Raton, Fla., manufacturing plant, as well as the remaining plasma collection centers and laboratory oper ations. Mr. Johns was general manager of MRLReference Laboratory, a clinical laborato ry specializing in the detection and diagnosis of infectious diseases, before joining the com pany in 1997. Before joining Nabi, Mr. Siskowski helped found Advanced Biologics, a clinical research organization specializing in antiinfectives. He spent 20 with Roche Laboratories, ultimately holding the position of product director for the antiinfectives franchise. Dr. David THOMASSEN Genencor names VP of business development for healthcare With an eye on expanding its healthcare business, Genencor International Inc. has named David Thomassen, Ph.D., its VP of business development of healthcare. Genencor, Palo Alto, Calif., is seeking to leverage its broad technology base to optimize drugs, develop protein therapeutics and thera peutic vaccines, and build various in vivo dis ease models with its imune mouse. This sum mer, the company signed collaboration and licensing deals with Epimmune and Phogen to develop vaccines. Dr. Thomassen joins Genencor after serv ing as director of business development at Chiron Corp., where he led a wide range of product and technology licensing and collabo ration deals. Dr. Thomassen received a masters in pharmacy from the University of Leiden, the Netherlands, and a Ph.D. in Pharmaceu tics from the University of Washington. He also completed his MBA from INSEAD, Fontainebleau, France. Dr. Roman URFER AGYTherapeutics appoints VP of drug discovery and development AGYTherapeutics has appointed Roman Urfer, Ph.D., VP of drug discov ery and development, focusing on compounds to treat central nervous system diseases. Dr. Urfer joins AGY, South San Francisco, Calif., from Novartis Pharma AG of Basel, Switzerland, where he served as head of one of the mature drugdiscovery programs. Dr. Urfer received a Ph.D. in biochemistry from the University of Basel, Switzerland. He has authored numerous publications and patents. Timothy G.WHITTEN Marketing and sales veteran joins Pharmacyclics With a background in overseeing huge drug launches, Timothy G. Whitten joins Pharma cyclics Inc. as senior VP of marketing and sales. Mr. Whitten, 44, joins Pharmacyclics from Bris tolMyers Squibb Co., where he most recently served as VP of global marketing for oncology. Among other roles at BMS, Mr. Whitten led the U.S. launch and marketing of the oncology product, Taxol. He also led marketing efforts for several other blockbuster drugs and was responsible for sales of more than $1.3 billion from 23 prod ucts. In his role at Pharmacyclics, Sunnyvale, Calif., Mr. Whitten initially is focusing on marketing Xcytrin Injection, which seeks to treat brain metatases, a type of cancer that spreads from one part of the body to the brain. Mr. Whitten earned his master’s in busi ness administration from Colgate Darden Graduate School of Business Administration at University of Virginia and received his pharmacy degree from West Virginia Univer sity. Specialty POOL Robert BUTCHOFSKY QLT appoints VP of marketing and sales planning Robert Butchofsky has been appointed VP of marketing and sales plan ning for ocular and oncol ogy products at QLT Inc., a leader in photodynamic therapy, a field of medicine using light activated drugs in the treatment of disease. Since joining QLT in 1998, Mr. Butchof sky has played an integral role in the success ful launch and commercialization of Visudyne, which treats wet agerelated macular degener ation. In his new role, he will be responsible for the ongoing marketing of Visudyne, a trademark of Novartis AG, as well as the cre ation of an oncology salesforce within QLT to market new products currently in develop ment. 78 N o v e mb e r / D e c e m b e r 2 00 1 PharmaVOICE TALENT pool Before joining Vancouverbased QLT, Mr. Butchofsky worked at Allergan, building an extensive background with ocular products including sales, health economics, worldwide medical marketing, and product manage ment. Mr. Butchofsky holds a bachelor of arts degree in biology and a masters of business administration from Pepperdine University. Clive A. MEANWELL David M.STACK The Medicines Company fills executivelevel positions The Medicines Com pany, which acquires and seeks approval for drugs in the late stage of devel opment, has named Clive A. Meanwell as executive chairman. Dr. Meanwell has served as president and CEO since the com pany’s formation in 1996. Reporting to him will be David M. Stack as president and CEO. Mr. Stack has served as senior VP of commercialization since April 2000. The two executives are coordi nating on strategic and operational matters. Dr. Meanwell and Mr. Stack both gained much of their pharmaceutical experience at HoffmannLa Roche. Before founding The Medicines Company, Dr. Meanwell was a partner and medical director at MPM Capital L.P., a venture capital firm. He holds M.D. and Ph.D. degrees from the University of Birmingham, United Kingdom. In addition to various positions at Roche, Mr. Stack has worked at an array of companies in the pharmaceutical and biotech fields, before joining The Medicines Company in April 2000. He holds a B.S. in biology from Siena College and a B.S. in pharmacy from Albany College of Pharmacy. Marvin SAMSON Sicor elects president and CEO In an expansion of his role at Sicor Inc., Marvin Samson has been elected president and CEO. Mr. Samson, who joined Irvine, Calif. based Sicor’s board in 2000, succeeds Carlo Salvi, Sicor’s largest stockholder, who will assume the role of vice chairman. Mr. Samson is a leader in injectable manu facturing and delivery systems, and was a founder, president, and CEO of ElkinsSinn, Inc. (now ESILederle) and Marsam Pharma ceuticals Inc. He is also the founder and CEO of Samson Medical Technologies L.L.C., which provides hospital and alternative site pharma cists with injectable drugdelivery systems and programs. Mr. Samson also has served as the chairman of the Generic Pharmaceutical Industry Association. Tony SCULLION Memory Pharmaceuticals appoints CEO Memory Pharmaceuti cals Corp., a privately held neuropharmaceutical drugdevelopment com pany, has appointed Tony Scullion as its CEO. The Montvale, N.J. based company, which specializes in the area of learning and memory disorders associated with aging as well as a number of diseases and conditions, is developing a diverse pipeline of cognition enhancers, or memoryenhancing drugs, based on its proprietary technology platform, which incorporates intellectual property discovered by Nobel Laureate, Eric Kandel, M.D., the scientific founder of the company. Before joining Memory Pharmaceuticals, Mr. Scullion was VP and head of global busi ness development at Glaxo Wellcome Plc. Mr. Scullion received his B.Sc. in physiology and his M.Sc. in pharmacology at the University of London. Douglas E. SWANSON Healthcare veteran to lead pharmacy sales at Omnicare Douglas E. Swanson, an 18year veteran of the drug distribution industry, has been named senior VP of sales and marketing at Omnicare Inc., a geriatric pharmaceuticalcare company. Mr. Swanson previously worked as presi dent of the health systems division at Bergen Brunswig Corp., which recently merged with AmeriSource Health Corp. to form AmerisourceBergen Corp. Mr. Swanson has a B.A. in political science from the University of Michigan. Dr. James THOMPSON Oncotech appoints VP of business development Oncotech, which is involved in the discov ery and development of diagnostic and phar maceutical products for cancer patients, has named James Thompson, M.D., Ph.D., as VP of business development. Before joining Oncotech, Dr. Thompson served as VP and medical director for a Cali forniabased pharmaceutical company, focused on developing anticancer vaccines. Addition ally, Dr. Thompson served as VP of technolo gy development and medical director at Impath. He holds numerous patents in the U.S. and abroad relating to the diagnosis and treatment of cancer. In his role at Oncotech, which is based in Tustin, Calif., Dr. Thompson is responsible for maintaining and establishing strategic rela tionships with genomicbased pharmaceutical and diagnostic companies worldwide. Dr. Thompson received his M.D. and Ph.D. from the University of California at Irvine (UCI) and is board certified in anatom ic pathology. Thomas H.TROBAUGH Serologicals names VP of global commercial operations division Thomas H. Trobaugh has joined Serologi cals Corp. as president of global commercial operations, a division responsible for oversee ing the company’s existing customers and helping to develop new business opportuni ties. Before joining Atlantabased Serologicals, Mr. Trobaugh was president of SmartLight Inc., a supplier of informatics and digital X ray film viewers for the radiography and mam mography markets. Drug Development POOL Mark EISENACH Industry innovator to lead Acurian through its next stage of growth Acurian Inc., a leader in accelerating the launch of clinical trials for phar maceutical and biotech nology companies, has named Mark Eisenach as its CEO. Before joining Acuri an, which is based in Hor sham, Pa., Mr. Eisenach held a variety of senior executive positions at Covance Inc., a drug development services company. In 1999, Mr. Eisenach founded Nexigent Inc., Covance’s e 79 PharmaVOICE N o v e mb e r / D e c e m be r 20 01 TALENT pool business subsidiary for the development of technologyenabled clinical trial services. “Acurian has identified a pressing need for the timely enrollment of clinical trials, both in terms of patient and physician participation, and is leading the way in delivering a next generation, datacentric solution,” Mr. Eise nach says. “I am thrilled to be joining a group of professionals dedicated to improving clini cal research.” Mr. Eisenach is a graduate of Harvard Col lege and of the Harvard Business School. Steven B. LEHRER DNA Sciences appoints new leadership Steven B. Lehrer takes over the running of DNA Sciences Inc., a genetics discovery and development company, following the resigna tion of Hugh Y. Rienhoff, Jr., M.D., as chair man and CEO. Mr. Lehrer, who was previous ly the company’s chief business officer, assumes the position of acting president and chief oper ating officer. He is working with the chief sci entific officer, Ray White, and the chief finan cial officer, Susan Berland to oversee the company’s research and commercial activities. The management change reflects the com pany’s decision to focus on two core business areas: application of genetics to clinical devel opment of pharmaceuticals and development of new technologies for genetic analysis. Dr. Nicholas J. NACLERIO Zyomyx appoints business officer Nicholas J. Naclerio, Ph.D., has been appointed as senior VP and chief business offi cer of Zyomyx Inc. Dr. Naclerio is responsible for the worldwide commercialization of Zyomyx’s protein biochip products and tech nologies. He is charged with managing corpo rate development, sales, and marketing and is responsible for launching products and ser vices for proteomics. Most recently, Dr. Naclerio founded Motorola’s lifesciences division where he served as VP and general manager of BioChip Systems. “As founder of Motorola’s lifesciences divi sion and VP of the BioChip systems group, Nick truly pioneered what has become an important genomic technology,” says Larry Cohen, Ph.D., CEO of Zyomyx, which is based in Hayward, Calif. “His breadth of expe rience in business development, as well as his superb teambuilding and leadership skills make Nick the right person for this position.” Zyomyx is working to develop a versatile platform technology to innovate protein anal ysis. 80 N o v e mb e r / D e c e m b e r 2 00 1 PharmaVOICE Emerging POOL Dr. Pascal BORDERIES Genaissance Pharmaceuticals names executive director Genaissance Pharma ceuticals Inc., which applies population geno mics, informatics, and clinical research to the development of personal ized medicines, has appointed Pascal Bor deries, M.D., to the posi tion of executive director, commercial devel opment and marketing. Dr. Borderies, 42, has a background in clinical development, product planning, and marketing. Reporting to Kevin Rakin, Genaissance president and CFO, Dr. Borderies is responsi ble for market analysis, product planning, and commercialization strategies. Dr. Borderies previously was the associate director of marketing for the U.S. subsidiary of SanofiSynthelabo, a European pharmaceutical company. Previously, he was with Synthelabo SA in France serving in a variety of roles. Dr. Avtar DHILLON Genetronics appoints president,CEO Genetronics Biomedical Corp. has appoint ed Avtar Dhillon as president and CEO, between Novirio and Sumitomo Pharmaceuti cals Co. Ltd. of Osaka, Japan. During his 20year career in the pharma ceutical industry, Mr. Egan has participated in the negotiation of more than 15 major phar maceutical product agreements with an aggre gate commercial value of more than $1 bil lion. Novirio is primarily focused on developing treatments for the hepatitis B virus, hepatitis C virus, and HIV/AIDS. Dr. John F. TALLMAN Helicon Therapeutics elects president,CEO John F. Tallman, Ph.D, known for his drugdiscovery research in the area of neuro science, has been elected to lead Helicon Ther apeutics Inc. as president and CEO. Dr. Tallman takes over the CEO position from George W. Carmany, III, who remains as chairman of the genomics company. Before joining Helicon, which is located in Farmingdale, N.Y., Dr. Tallman was chief sci entific officer of Neurogen Corp. Douglass C. WATSON GenSci Regeneration Sciences names president and CEO GenSci Regeneration Sciences Inc. has formally appointed Douglass C. Watson as president and CEO, roles he has been serving on an interim basis since August 2001. replacing Grant Denison, who remains on Genetronics’ board of directors. Dr. Dhillon was most recently VP of MDS Capital Corp., a North American venture cap ital firm focused on healthcare and lifesci ences companies. Dr. Dhillon is a member of the College of Physicians and Surgeons (Canada), the College of Family Practioners (Canada), and the British Columbia and Canadian Medical Asso ciations. He received his B.Sc. (honors) in physiology and M.D. from the University of British Columbia. Dr. Dhillon serves on the Securities Practice Advisory Committee for the British Columbia Securities Commission. Genetronics Biomedical, a San Diego sub sidiary of Genetronics Inc., specializes in tar geted intracellular delivery of largemolecule therapeutics. James J. EGAN Novirio selects executive to direct strategic development Novirio Pharmaceuti cals Ltd. has named James J. Egan, J.D., as senior VP of business and corporate development. Mr. Egan is charged with directing the company’s strategic development, including both inlicensing and outlicensing, joint ventures, strategic alliances, and acquisitions. Mr. Egan previously has worked as a con sultant for the Cambridge, Mass.based bio pharmaceutical company, helping to negotiate a codevelopment and marketing deal TALENT pool Mr. Watson joined Torontobased GenSci in 1996 as senior VP of business development of GenSci OrthoBiologics, a subsidiary of Gen Sci, and has since served in senior capacities at both the parent company and the subsidiary. “We are pleased that Mr. Watson will be at the helm of GenSci Regeneration as we intro duce exciting new products to the market place and work to grow the company’s revenue and market share,” says Dr. James S. Trotman, chairman. Mr. Watson served in the U.S. Navy from 1973 to 1977 and served in the Naval Reserve from 1977 to 2000 retiring as a Captain. He earned his bachelor of science in business administration from Auburn University, and has an MBA from Georgia State University, both with concentrations in marketing. GenSci Regeneration Sciences Inc. is focused on developing novel approaches to bone repair and regeneration. 81 PharmaVOICE N o v e mb e r / D e c e m b e r 20 01 Service POOL Carin CANALE Susan E. Atkins & Assoc.names VP Susan E. Atkins & Associates, San Diego’s largest communication consulting firm focused in the life sciences, has promoted Carin Canale to VP. The company also said it had taken on sev eral new employees and added to its client ros ter. With the new clients, Atkins &Associates has annualized billings approaching $3 mil lion. Ms. Canale, formerly senior account direc tor, will lead strategic planning for the grow ing agency, provide support and supervision for client services, continue to develop new business opportunities, and serve as a mentor to company employees. Dr. Sophia C. FOURIE Regulatory/Clinical Consultants appoints medical affairs executive Sophia C. Fourie has joined Regulatory/Clini cal Consultants Inc. as associate director of medi cal affairs. Dr. Fourie comes to RxCCI, Kansas City, Mo., from Kansas State Uni versity, where she served as medical research advisor for the KSU Cen ter for Basic Cancer Research &BioServe Space Technologies, a NASAsponsored commercial space center. She obtained her medical degree from the University of Pretoria, South Africa, and is a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. “Dr. Fourie’s comprehensive pharmaceuti cal experience will be an invaluable catalyst to assist clients and foster RxCCI’s continued growth,” says Diane Seif, president. RXCCI monitors pharmaceutical, biotech nology, medical device, and medical research on new drug applications and related drug studies. Patrick FOURTEAU Ventiv’s Europe executive given expanded role Ventiv Health Inc., a provider of compre hensive marketing and sales solutions to the healthcare industry, has appointed Patrick Fourteau, president of Ventiv Health Europe, to the additional position of president of Ven tiv Health U.S. Sales. Mr. Fourteau takes over the responsibilities of William Pollock, who has left the New York Citybased company. Mr. Fourteau joined Ventiv Health in Jan uary 2000 with an extensive pharmaceutical and healthcare background, including four years at St. Jude Medical, a worldwide leader in pacemakers, and 16 years at Eli Lilly & Co.. A native of France, Mr. Fourteau received a master’s in business administration from Har vard Business School and a master’s degree in mathematics and a bachelor’s degree in math ematics/computer sciences, Phi Beta Kappa, both from the University of California at Berkeley. John FRIESNER MDS Pharma appoints VP of business development MDS Pharma Services, a developer of drug discovery and preclinical programs, has appointed John Friesner as VP of business development, for its discovery and preclinical business unit. Mr. Friesner, who is based in Bothell, Wash., oversees discovery and preclinical busi ness development directors in North America, Europe, and Asia. Before joining MDS Pharma Services, Mr. Friesner led business development efforts for a division of American Home Products. MDS Pharma Services is a unit of Toronto based MDS Inc. James MCDERMOTT Dr. Kevin PANG Decision Resources names twoVPs Decision Resources Inc., a pharmaceutical research and consulting company, has appoint ed two new VPs — James McDermott and Kevin Pang. Mr. McDermott joined Decision Resources, Waltham, Mass., in March 2001, and was given a broad charter to reposition the company’s consulting business, which he helped to transform into a more strategically oriented practice. Mr. McDermott’s background is in strate gy consulting, and he has been a VP at SRI Consulting, and a principal at Nervewire and CSC Index. Mr. McDermott holds a B.S. in mechanical engineering from Tufts University. Dr. Pang joined Decision Resources in August 2000 as the senior director of the com pany’s largest product unit, and he has played a key role in developing Decision Resources’ global strategy. Previously, Dr. Pang was a senior scientist at Ontogeny, where he led the diabetes and neurobiology teams. He holds a B.S./B.A. from U.C. Berkeley, a Ph.D. in physiology and biophysics from Harvard Uni versity, and an M.B.A. from Bentley College. Mary NOKES Direct marketing company names manager Mary Nokes has been appointed business development manager at Pharmaceutical Direct Inc., a direct marketing company based in Dover, N.J. Ms. Nokes has more than 25 years of sales, marketing, and public relations experience in the pharmaceutical industry. Before joining Pharmaceutical Direct, Ms. Nokes was a principal in a communications firm in Washington, D.C. Susan Murphy WARREN Parexel appoints VP of corporate marketing and strategy Parexel International Corp., a pharmaceu tical outsourcing organization, has named Susan Murphy Warren as VP of corporate marketing and strategy, overseeing the man agement and administration of the company’s marketing, public relations, and strategic planning activities worldwide. Ms. Murphy Warren has 18 years of expe rience in the biomedical industry in market ing, strategic planning, and commercial oper ations. Before joining Parexel, Boston, she was TALENT pool 82 N o v e mb e r / D e c e m b e r 20 01 PharmaVOICE VP of marketing and sales at Mosaic Tech nologies Inc., a genomics tools company serv ing the pharmaceutical and biotech industries. Ms. Murphy Warren received her M.B.A. from Harvard University and M.A. in interna tional studies from the American University. Media POOL Barbara J. CULLITON TIGR appoints publishing executive The Institute for Genomic Research, also known as TIGR, has appointed Barbara J. Cul liton as VP for publishing and editor in chief of the Genome News Network. Ms. Culliton is charged with developing and overseeing TIGR’s publishing activities, as well as GNN’s services. GNN, which was founded by Ms. Culliton and her team at Cel era Genomics, has recently been acquired by Rockville, Md.based TIGR, a nonprofit research institute specializing in genomic sci ence. GNN produces an online news magazine about genomics in medicine, biomedical research, and agriculture. Mike JAGLOIS Drugstore.com appoints marketing VP Drugstore.com Inc., an online drugstore and information site, has appointed Mike Jaglois as VP of marketing. A 25year veteran of consumer marketing, Mr. Jaglois comes to drugstore.com, Bellevue, Wash., from McCannErickson, where he served as senior VP and brand director, with responsi bility for account management, new business development, and brand strategy for all clients. Agency POOL Nick FLORENTINO Dudnyk Healthcare Group hires interactive information architect With more than a decade of marketing knowhow, Nick Florentino has joined the interactive team at Dud nyk Healthcare Group as director of user experi ence. He is responsible for establishing the informa tion architecture process and the design of interac tive business solutions for agency clients. Most recently, Mr. Florentino was the director of user experience for Concellera, an Internet software development company. Previously, he was director of information architecture for US Interactive. Since 1991, Mr. Florentino has worked for a variety of advertising agencies, including the Weight man Group, D’Arcy Masius Benton & Bowles and Tandem Associates. Mr. Florentino, 34, has a master’s degree in instructional technology from Bloomsburg University and a bachelor’s degree from Tem ple University. Bruce LEHMAN Lehman Millet CEO named charter member of HarvardMIT Board The HarvardMIT Division of Health Sci ences and Technology has appointed Bruce Lehman as a charter member of its advisory council. Mr. Lehman is president and CEO of Lehman Millet Inc., a healthcare advertis ing agency focused on the device and diagnos tic industry. The 40member advisory council includes Nobel laureates, device industry CEOs, heads of venture capital groups dedicated to the device industry, and leaders in the clinical community. Health Sciences and Technology is a selec tive postgraduate program that integrates engineering, science, technology, and medicine. Through crossdisciplinary train ing, HST enables its graduates to better understand the root causes of disease and develop new pharmaceuticals and devices. The HST program is expanding to include a sub stantial business education track, and the advi sory council was set up to further this effort. “Over my 20 plus years in the industry, I have seen many innovative ideas and technolo gies gather dust not because the concept was flawed, not because the technology didn’t work, not because the product was lacking, but because there was an inherent disconnect between customer needs and the positioning of the innovation in the marketplace,” Mr. Lehman says. “It is not surprising that the HST program would be one of the first in the country to appreciate this vacuum and to develop a program that will ultimately be a source of business leaders as well as scientific and medical leaders.” John SPERZEL Lehman Millet taps executive as head of diagnostic practice John Sperzel has joined Lehman Millet Inc. as VP and director of the agency’s diagnostic practice. In this position, which has just been creat ed, Mr. Sperzel’s focus is on providing device and diagnostic clients with senior counsel. “As a former Lehman Millet client, I can attest to the agency’s exceptionally high stan dards,” Mr. Sperzel says of the Bostonbased healthcare agency. “Lehman Millet certainly helped me drive my businesses forward by marrying insightful strategy with great cre ative. The agency has a history of developing programs to address very specific marketing challenges — from introducing disruptive technologies to repositioning and rejuvenat ing mature products.” Mr. Sperzel, 38, previously was VP of the worldwide hemostasis and criticalcare busi ness units at Instrumentation Laboratory, a Mass.based diagnostics company. Please send your personnel announcements to email@example.com. Healthcare among fastest growing workforces According to U.S. Bureau of Labor Statistics data, healthcare is among the fastestgrowing segments in the work force, currently employing 12 million people and providing job opportunities for as many as 4 million new employees over the next eight years. 75% of U.S. workingage women are in the labor market. By 2050, close to onehalf of the U.S, population will be made up of Asians,Hispanics,AfricanAmericans, and other minority groups. ADIVERSEWORKFORCE INDUSTRY SNAPSHOT